1 |
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 2021;397:99-111.
DOI
|
2 |
Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021;384:2187-201.
DOI
|
3 |
Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021;384:2092-101.
DOI
|
4 |
Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124-30.
DOI
|
5 |
Warkentin TE, Cuker A. COVID-19: vaccine-induced immune thrombotic thrombocytopenia (VITT) [Internet]. Waltham (MA): UpToDate; 2021 [cited 2021 Jun 15]. Available from: https://www.uptodate.com/contents/covid-19-vaccine-induced-immune-thrombotic-thrombocytopenia-vitt?search=COVID-19:%20vaccine-induced%20immune%20thrombotic%20thrombocytopenia%20(VITT)&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
|
6 |
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020;18:1023-6.
DOI
|
7 |
Oldenburg J, Klamroth R, Langer F, Albisetti M, von Auer C, Ay C, et al. Diagnosis and management of vaccine-related thrombosis following AstraZeneca COVID-19 vaccination: guidance statement from the GTH. Hamostaseologie 2021;41:184-9.
DOI
|
8 |
U.S. Food and Drug Administration. COVID-19 vaccines [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2021 [cited 2021 May 15]. Available from: https://www.fda.gov/emergency-preparednessand-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
|
9 |
European Medicine Agency. COVID-19 vaccines [Internet]. Amsterdam (Netherlands): European Medicine Agency; 1995-2021 [cited 2021 May 5]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatmentsvaccines/covid-19-vaccines.
|
10 |
International Society on Thrombosis and Haemostasis. ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine-Induced Immune Thrombotic Thrombocytopenia (Updated 20 April, 2021) [Internet]. Carrboro (NC): ISTH; 2021 [cited 2021 Jun 15]. Available from: https://www.isth.org/resource/resmgr/ISTH_VITT_Guidance_2.pdf.
|
11 |
Carli G, Nichele I, Ruggeri M, Barra S, Tosetto A. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine. Intern Emerg Med 2021;16:803-4.
DOI
|
12 |
Guidance produced by the Expert Haematology Panel (EHP) focussed on Vaccine induced Thrombosis and Thrombocytopenia (VITT) [Internet]. London: British Society for Haematology; 2021 [cited 2021 Jun 15]. Available from: https://b-s-h.org.uk/about-us/news/guidance-producedby-the-expert-haematology-panel-ehp-focussed-on-vaccine-inducedthrombosis-and-thrombocytopenia-vitt/.
|
13 |
Nazy I, Sachs UJ, Arnold DM, McKenzie SE, Choi P, Althaus K, et al. Recommendations for the clinical and laboratory diagnosis of vaccine-induced immune thrombotic thrombocytopenia (VITT) for SARS-CoV-2 infections: Communication from the ISTH SSC Subcommittee on Platelet Immunology. J Thromb Haemost 2021;19:1585-8.
DOI
|
14 |
See I, Su JR, Lale A, Woo EJ, Guh AY, Shimabukuro TT, et al. US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021. JAMA 2021;325:2448-56.
DOI
|
15 |
Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia (VITT): what we know and don't know. Blood 2021:blood.2021012152.
|
16 |
Thaler J, Ay C, Gleixner KV, Hauswirth AW, Cacioppo F, Grafeneder J, et al. Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT). J Thromb Haemost 2021;19:1819-22.
DOI
|
17 |
Lee EJ, Cines DB, Gernsheimer T, Kessler C, Michel M, Tarantino MD, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021;96:534-7.
DOI
|
18 |
Iba T, Levy JH, Levi M, Thachil J. Coagulopathy in COVID-19. J Thromb Haemost 2020;18:2103-9.
DOI
|
19 |
Mitchell WB, Davila J, Keenan J, Jackson J, Tal A, Morrone KA, et al. Children and young adults hospitalized for severe COVID-19 exhibit thrombotic coagulopathy. Pediatr Blood Cancer 2021;68:e28975.
|
20 |
Whi worth HB, Sartain SE, Kumar R, Armstrong K, Ballester L, Betensky M, et al. Rate of thrombosis in children and adolescents hospitalized with COVID-19 or MIS-C. Blood 2021;blood.2020010218.
|
21 |
Helms JM, Ansteatt KT, Roberts JC, Kamatam S, Foong KS, Labayog JS, et al. Severe, refractory immune thrombocytopenia occurring after SARS-CoV-2 vaccine. J Blood Med 2021;12:221-4.
DOI
|
22 |
Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med 2021;384:2254-6.
DOI
|
23 |
Muir KL, Kallam A, Koepsell SA, Gundabolu K. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med 2021;384:1964-5.
DOI
|
24 |
Medicines and Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting - Data included: 09/12/2020 to 05/04/2021 [Internet]. GOV.UK; 2021 [cited 2021 Jun 15]. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.
|
25 |
Shin SM. Second case of thrombocytopenic thrombosis in South Kore. YONHAP NEWS [Internet]. 2021 Jun 16 [cited 2021 Jun 16]. Available from: https://www.yna.co.kr/view/AKR20210616107651530?input=1195m.
|
26 |
National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) [Internet]. Ottawa (ON): Public Health Agency of Canada; 2021 [cited 2021 Jun 15]. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/immunization/nationaladvisory-committee-on-immunization-naci/recommendations-usecovid-19-vaccines/recommendations-use-covid-19-vaccines-en.pdf.
|
27 |
Gras-Champel V, Liabeuf S, Baud M, Albucher JF, Benkebil M, Boulay C, et al. Atypical thrombosis associated with VaxZevria (AstraZeneca) vaccine: data from the French Network of Regional Pharmacovigilance Centres. Therapie 2021:S0040-5957(21)00130-X.
|
28 |
Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med 2015;373:252-61.
DOI
|
29 |
Obeng EA, Harney KM, Moniz T, Arnold A, Neufeld EJ, Trenor CC. Pediatric heparin-induced thrombocytopenia: prevalence, thrombotic risk, and application of the 4Ts scoring system. J Pediatr 2015;166:144-50.
DOI
|
30 |
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020;324:782-93.
DOI
|
31 |
World Health Organization. Coronavirus disease (COVID-19) [Internet]. Geneva (Switzerland): World Health Organization; 2021 [cited 2021 Jun 15]. Available from: https://extranet.who.int/pqweb/vaccines/covid-19-vaccines.
|
32 |
Update: Thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2021 [cited 2021 Jun 15]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-05-12/07-COVID-Shimabukuro-508.pdf.
|
33 |
Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost 2016;116:813-22.
DOI
|